Entrada Therapeutics (TRDA) Assets Average (2021 - 2026)

Entrada Therapeutics' Assets Average history runs 6 years deep, the most recent figure standing at $356.4 million for Q1 2026.

• In Q1 2026, Assets Average fell 29.61% year-over-year to $356.4 million; the TTM figure through Mar 2026 stood at $356.4 million (down 29.61% YoY), while the FY2025 annual figure was $451.8 million, down 9.22% from the prior year.
• Assets Average was $356.4 million for Q1 2026 at Entrada Therapeutics, down from $395.1 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $568.3 million in Q3 2024 to a low of $263.3 million in Q4 2022.
• Historically, Assets Average has averaged $428.4 million across 5 years, with a median of $467.6 million in 2025.
• The sharpest annual moves came in 2023 and 2026: Assets Average soared 81.23% in 2023, then retreated 29.61% in 2026.
• A 5-year view of Assets Average shows it stood at $263.3 million in 2022, then soared by 81.23% to $477.1 million in 2023, then climbed by 13.28% to $540.5 million in 2024, then fell by 26.89% to $395.1 million in 2025, then slipped by 9.79% to $356.4 million in 2026.
• The last three Assets Average figures came in at $356.4 million (Q1 2026), $395.1 million (Q4 2025), and $430.8 million (Q3 2025), per Business Quant data.